Shots:
- InnoCare to receive $125M as up front & is eligible to receive ~ $812.5M as development & commercial milestones, following the achievement of definite milestones along with royalties on sales of any product resulting from the collaboration
- Biogen to get exclusive rights for orelabrutinib to treat MS globally & other autoimmune diseases outside of China while InnoCare will retain exclusive WW rights to the therapy in the field of oncology & other autoimmune diseases in China
- Orelabrutinib is a covalent BTKi with high selectivity & has the potential to cross the BBB. Additionally, the therapy is currently being evaluated in a P-II trial for RRMS
Click here to read full press release/ article | Ref: Globe Newswire | Image: Innocare
The post Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis first appeared on PharmaShots.
